Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study
KA Ellenbogen,
BS Stambler,
MA Wood,
PT Sager,
RC Wesley Jr,
MC Meissner,
RG Zoble,
LK Wakefield,
KT Perry,
and
JT Vanderlugt
Department of Medicine, Medical College of Virginia, Richmond 23298-0053, USA.
OBJECTIVES: Currently available antiarrhythmic drugs have limited efficacy for short-term, rapid termination of atrial fibrillation and atrial flutter. BACKGROUND: Ibutilide fumarate is an investigational class III antiarrhythmic agent that prolongs repolarization by increasing the slow inward sodium current and by blocking the delayed rectifier current. It can be administered intravenously and has a rapid onset of electrophysiologic effects. METHODS: The efficacy and safety of ibutilide were studied in 200 patients with atrial flutter > 3 h in duration or atrial fibrillation 3 h to 90 days in duration. Patients were randomized to receive a single intravenous dose of placebo or an infusion of ibutilide fumarate at 0.005, 0.010, 0.015 or 0.025 mg/kg body weight over 10 min. Conversion was defined as termination of the atrial arrhythmia during or within 60 min after infusion. Forty-one patients received placebo and 159 received ibutilide (0.005 mg/kg [n = 41], 0.010 mg/kg [n = 40], 0.015 mg/kg [n = 38] or 0.025 mg/kg [n = 40]). RESULTS: The arrhythmia terminated in 34% of drug-treated patients. The rates of successful arrhythmia termination were 3% for placebo and 12%, 33%, 45% and 46%, respectively, for 0.005-, 0.010-, 0.015- and 0.025-mg/kg ibutilide. The placebo and 0.005-mg/kg ibutilide groups had lower success rates than all other dose groups (p < 0.05). The mean time to termination of the arrhythmia was 19 min (range 3 to 70) from the start of infusion. Successful arrhythmia termination was not affected by enlarged left atrial diameter, decreased ejection fraction, presence of valvular heart disease or the use of concomitant medications (beta-adrenergic blocking agents, calcium channel blocking agents or digoxin). Arrhythmia termination was not predicted by the magnitude of corrected QT interval prolongation but was associated with a shorter duration of atrial arrhythmia. The most frequent adverse events in ibutilide-treated patients were sustained and nonsustained polymorphic ventricular tachycardia (3.6%). All patients with sustained polymorphic ventricular tachycardia were successfully treated with direct current cardioversion and had no recurrence. The occurrence of proarrhythmia did not correlate with ibutilide plasma concentration. CONCLUSIONS: These data demonstrate that ibutilide is able to rapidly terminate atrial fibrillation and atrial flutter.
This article has been cited by other articles:
|
|
|
|
 
G. M. Marcus, E. Keung, and M. M. Scheinman
The year in review of clinical cardiac electrophysiology.
J. Am. Coll. Cardiol.,
August 25, 2009;
54(9):
777 - 787.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Geller, K. Egstrup, P. Kulakowski, M. Rosenqvist, M. A. Jansson, A. Berggren, N. Edvardsson, P. Sager, and H. J. Crijns
Rapid Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009
J. Clin. Pharmacol.,
March 1, 2009;
49(3):
312 - 322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst
CHAPTER 29 Atrial Fibrillation
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Roy, C. M. Pratt, C. Torp-Pedersen, D. G. Wyse, E. Toft, S. Juul-Moller, T. Nielsen, S. L. Rasmussen, I. G. Stiell, B. Coutu, et al.
Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation: A Phase 3, Randomized, Placebo-Controlled Trial
Circulation,
March 25, 2008;
117(12):
1518 - 1525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Shantsila, T. Watson, and G. Y. Lip
Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias
Europace,
September 1, 2007;
9(suppl_4):
iv37 - iv44.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace,
September 1, 2006;
8(9):
651 - 745.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
854 - 906.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
e149 - e246.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
e257 - e354.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
700 - 752.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Eur. Heart J.,
August 2, 2006;
27(16):
1979 - 2030.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Korantzopoulos, T M Kolettis, A Papathanasiou, K K Naka, P Kolios, I Leontaridis, A Draganigos, C S Katsouras, and J A Goudevenos
Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation
Heart,
May 1, 2006;
92(5):
631 - 634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Roy, B. H. Rowe, I. G. Stiell, B. Coutu, J. H. Ip, D. Phaneuf, J. Lee, H. Vidaillet, G. Dickinson, S. Grant, et al.
A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation
J. Am. Coll. Cardiol.,
December 21, 2004;
44(12):
2355 - 2361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Blaauw, H. Gogelein, R.G. Tieleman, A. van Hunnik, U. Schotten, and M.A. Allessie
"Early" Class III Drugs for the Treatment of Atrial Fibrillation: Efficacy and Atrial Selectivity of AVE0118 in Remodeled Atria of the Goat
Circulation,
September 28, 2004;
110(13):
1717 - 1724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Chiladakis, A. Kalogeropoulos, N. Patsouras, and A. S. Manolis
Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter
J. Am. Coll. Cardiol.,
August 18, 2004;
44(4):
859 - 863.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Hongo, S. Themistoclakis, A. Raviele, A. Bonso, A. Rossillo, K. A. Glatter, Y. Yang, and M. M. Scheinman
Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents
J. Am. Coll. Cardiol.,
August 18, 2004;
44(4):
864 - 868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Reisinger, E. Gatterer, W. Lang, T. Vanicek, G. Eisserer, T. Bachleitner, C. Niemeth, F. Aicher, W. Grander, G. Heinze, et al.
Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset
Eur. Heart J.,
August 1, 2004;
25(15):
1318 - 1324.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Hohnloser, P. Dorian, M. Straub, K. Beckmann, and P. Kowey
Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter
J. Am. Coll. Cardiol.,
July 7, 2004;
44(1):
99 - 104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C-J A Lindholm, O Fredholm, S-J Moller, N Edvardsson, T Kronvall, T Pettersson, V Firsovaite, A Roijer, C J Meurling, P G Platonov, et al.
Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil
Heart,
May 1, 2004;
90(5):
534 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Amabile and A. P. Spencer
Keeping Your Patient With Heart Failure Safe: A Review of Potentially Dangerous Medications
Arch Intern Med,
April 12, 2004;
164(7):
709 - 720.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, R. J. Goodrow Jr, et al.
Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2004;
9(1_suppl):
S65 - S83.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Mazza, M. S. Fera, I. Bisceglia, F. Bettiol, G. Pulignano, P. Tanzi, C. Gaudio, and E. Giovannini
Efficacy and safety of ibutilide vs. transoesophageal atrial pacing for the termination of type I atrial flutter
Europace,
January 1, 2004;
6(4):
301 - 306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. McNamara, L. J. Tamariz, J. B. Segal, and E. B. Bass
Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography
Ann Intern Med,
December 16, 2003;
139(12):
1018 - 1033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Committee Members, C. Blomstrom-Lundqvist, M. M. Scheinman, E. M. Aliot, J. S. Alpert, H. Calkins, A. J. Camm, W. B. Campbell, D. E. Haines, K. H. Kuck, et al.
ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias --executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) Developed in Collaboration with NASPE-Heart Rhythm Society
J. Am. Coll. Cardiol.,
October 15, 2003;
42(8):
1493 - 1531.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Blomstrom-Lundqvist, M. M. Scheinman, E. M. Aliot, J. S. Alpert, H. Calkins, A. J. Camm, W. B. Campbell, D. E. Haines, K. H. Kuck, B. B. Lerman, et al.
ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias*--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias)
Circulation,
October 14, 2003;
108(15):
1871 - 1909.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Committee Members, C. Blomstrom-Lundqvist, M. M Scheinman, E. M Aliot, J. S Alpert, H. Calkins, A.J. Camm, W.B. Campbell, D. E Haines, K. H Kuck, et al.
ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: A Report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias)Developed in collaboration with NASPE-Heart Rhythm Society
Eur. Heart J.,
October 2, 2003;
24(20):
1857 - 1897.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Capucci and D. Aschieri
Antiarrhythmic drug therapy: what is certain and what is to come
Eur. Heart J. Suppl.,
September 1, 2003;
5(suppl_H):
H8 - H18.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A Wakai and J O O'Neill
Emergency management of atrial fibrillation
Postgrad. Med. J.,
June 1, 2003;
79(932):
313 - 319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Rosen
Blunderbuss to Mickey Mouse: The Evolution of Antiarrhythmic Targets
Circulation,
September 3, 2002;
106(10):
1180 - 1182.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cheng, K. Glatter, Y. Yang, S. Zhang, R. Lee, and M. M. Scheinman
Electrophysiological Response of the Right Atrium to Ibutilide During Typical Atrial Flutter
Circulation,
August 13, 2002;
106(7):
814 - 819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Aronow
Management of the Older Person With Atrial Fibrillation
J. Gerontol. A Biol. Sci. Med. Sci.,
June 1, 2002;
57(6):
M352 - 363.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
Circulation,
October 23, 2001;
104(17):
2118 - 2150.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Glatter, P. C. Dorostkar, Y. Yang, R. J. Lee, G. F. Van Hare, E. Keung, G. Modin, and M. M. Scheinman
Electrophysiological Effects of Ibutilide in Patients With Accessory Pathways
Circulation,
October 16, 2001;
104(16):
1933 - 1939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
Eur. Heart J.,
October 2, 2001;
22(20):
1852 - 1923.
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
J. Am. Coll. Cardiol.,
October 1, 2001;
38(4):
1231 - 1265.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
J. Am. Coll. Cardiol.,
October 1, 2001;
38(4):
1266 - 1266.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Darpo
Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes
Eur. Heart J. Suppl.,
September 1, 2001;
3(suppl_K):
K70 - K80.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Glatter, Y. Yang, K. Chatterjee, G. Modin, J. Cheng, S. Kayser, and M. M. Scheinman
Chemical Cardioversion of Atrial Fibrillation or Flutter With Ibutilide in Patients Receiving Amiodarone Therapy
Circulation,
January 16, 2001;
103(2):
253 - 257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Alpert
Medical Cardioversion of Atrial Fibrillation
Chest,
June 1, 2000;
117(6):
1529 - 1531.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Reiffel and M. Blitzer
The Actions of Ibutilide and Class Ic Drugs on the Slow Sodium Channel: New Insights Regarding Individual Pharmacologic Effects Elucidated Through Combination Therapies
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 2000;
5(3):
177 - 181.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. K. Doshi and B. N. Singh
Reviews: Pure Class III Antiarrhythmic Drugs: Focus on Dofetilide
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 2000;
5(4):
237 - 247.
[PDF]
|
|
|
|
|
|
|
H. Oral, B. P. Knight, C. Sticherling, M. H. Kim, R. L. Baker, S. P. Chough, K. Wasmer, F. Pelosi JR, G. F. Michaud, A. M. Fendrick, et al.
Cost Analysis of Transthoracic Cardioversion of Atrial Fibrillation With and Without Ibutilide Pretreatment
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 2000;
5(4):
259 - 266.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. Houltz, B. Darpo, K. Swedberg, P. Blomstrom, H.J.G.M. Crijns, S.M. Jensen, E. Svernhage, and N. Edvardsson
Comparison of QT dispersion during atrial fibrillation and sinus rhythm in the same patients, at normal and prolonged ventricular repolarization
Europace,
January 1, 2000;
2(1):
20 - 31.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. T. VanderLugt, T. Mattioni, S. Denker, D. Torchiana, T. Ahern, L. K. Wakefield, K. T. Perry, and P. R. Kowey
Efficacy and Safety of Ibutilide Fumarate for the Conversion of Atrial Arrhythmias After Cardiac Surgery
Circulation,
July 27, 1999;
100(4):
369 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Oral, J. J. Souza, G. F. Michaud, B. P. Knight, R. Goyal, S. A. Strickberger, and F. Morady
Facilitating Transthoracic Cardioversion of Atrial Fibrillation with Ibutilide Pretreatment
N. Engl. J. Med.,
June 17, 1999;
340(24):
1849 - 1854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Lee and E. W. Lee
Ionic Mechanism of Ibutilide in Human Atrium: Evidence for a Drug-Induced Na+ Current Through a Nifedipine Inhibited Inward Channel
J. Pharmacol. Exp. Ther.,
July 1, 1998;
286(1):
9 - 22.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M A Vos, S R Golitsyn, K Stangl, M Y Ruda, L Van Wijk, J D Harry, K T Perry, P Touboul, G Steinbeck, and H J J Wellens
Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation
Heart,
June 1, 1998;
79(6):
568 - 575.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. T. Murray
Ibutilide
Circulation,
February 10, 1998;
97(5):
493 - 497.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Stambler, M. A. Wood, and K. A. Ellenbogen
Antiarrhythmic Actions of Intravenous Ibutilide Compared With Procainamide During Human Atrial Flutter and Fibrillation : Electrophysiological Determinants of Enhanced Conversion Efficacy
Circulation,
December 16, 1997;
96(12):
4298 - 4306.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Yamashita, Y. Murakawa, K. Sezaki, M. Inoue, N. Hayami, Y. Shuzui, and M. Omata
Circadian Variation of Paroxysmal Atrial Fibrillation
Circulation,
September 2, 1997;
96(5):
1537 - 1541.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Gallik, J. Altamirano, and B. N. Singh
Review : Restoring Sinus Rhythm in Patients with Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 1997;
2(2):
135 - 144.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. N. Singh
Searching for the Ideal Class III Antiarrhythmic Agent: How Pure Should They Be?
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 1997;
2(4):
239 - 242.
[PDF]
|
|
|
|
